Humacyte Reports Positive Interim Phase 3 Results for ATEV in Female Dialysis Access Patients
Key Highlights
- ATEV meets primary endpoint with statistical superiority over standard of care (autologous AV fistula) in female dialysis access patients.
- Humacyte intends to file a supplemental Biologics License Application (BLA) with the FDA in H2 2026, targeting adult patients at increased risk of AV fistula maturation failure.
- ATEV recipients averaged 91 more catheter-free days (total 220) than those with AV fistula (129 days) in first 80 patients, a highly significant result (p=0.00070).
- ATEV demonstrated a lower infection rate (6 per 100 patient-years) compared to AV fistula (23 per 100 patient-years). No study access-associated infections reported in ATEV group.
- Study enrollment now terminated early as per protocol following positive interim analysis; ongoing monitoring of enrolled patients will continue.
- Results to be presented at the Society for Vascular Surgery’s Annual Meeting in Boston, Women’s Health seminar, June 11, 2026.
- ATEV previously approved by FDA (Dec 2024) for vascular injury; late-stage trials ongoing for broader vascular indications.
Detailed Analysis and Investor-Relevant Insights
Humacyte, Inc. (Nasdaq: HUMA), a leading commercial-stage biotechnology company specializing in bioengineered human tissues, has announced positive topline interim results from its pivotal Phase 3 V012 study evaluating the acellular tissue engineered vessel (ATEV) in female patients requiring dialysis access.
Study Design and Results
The V012 trial is a Phase 3, multi-center, open-label, randomized, two-arm comparative study conducted in the U.S., enrolling up to 150 patients (120 currently enrolled). The focus is on adult females with end-stage kidney disease who are at higher risk of AV fistula maturation failure—a group with substantial unmet medical need.
A pre-specified interim analysis was performed after 80 patients completed 12 months of follow-up. The primary efficacy endpoint was the total number of days free from an in-dwelling catheter within the first year after access placement or until access abandonment.
- ATEV recipients had an average of 220 catheter-free days versus 129 days for AV fistula patients—a difference of 91 days (~3 months), statistically significant (p=0.00070).
- Reduced infection risk: Infection rate for ATEV was 6 per 100 patient-years, significantly lower than the 23 per 100 patient-years seen with AV fistula. Notably, there were no access-associated infections in the ATEV group versus three in the AV fistula group.
- Safety profile: No spontaneous ruptures in either group; overall benefit-risk profile for ATEV was favorable with no new or unexpected safety signals.
Study Implications and Regulatory Pathway
Given the positive interim results, study enrollment will be terminated as per protocol, and all currently enrolled patients will continue to be followed for safety and efficacy as planned. Humacyte now plans to file a supplemental BLA with the FDA in the second half of 2026, targeting approval for adult patients with end-stage kidney disease at increased risk for AV fistula maturation failure.
Market and Clinical Significance
There are over 800,000 Americans with end-stage kidney disease, and nearly 500,000 rely on hemodialysis. Establishing a durable and infection-resistant access point is essential, especially for women and those with challenging anatomy, where AV fistula often fails. Catheter use is associated with high infection rates and other complications, further highlighting the value proposition of the ATEV.
Humacyte’s ATEV is a bioengineered human tissue designed to be universally implantable and available off-the-shelf, addressing surgeon and patient needs for reliable, infection-resistant vascular access. The product’s demonstrated reduction in catheter use and infection rates could translate to better patient outcomes and lower healthcare costs, representing a significant advancement over current standard of care.
Broader Pipeline and Regulatory Status
ATEV received FDA approval in December 2024 for vascular injury indications and remains in late-stage trials for multiple vascular applications, including AV access in hemodialysis and peripheral artery disease (PAD). The 6mm ATEV platform has received RMAT and FDA Fast Track designations, as well as priority status from the U.S. Secretary of Defense for vascular trauma.
Shareholder-Relevant and Price-Sensitive Considerations
- Positive Phase 3 data and statistical superiority may drive significant investor interest and potential share price appreciation, especially given the large target market and unmet need in female dialysis patients.
- Early termination of enrollment due to meeting primary endpoint is a strong indicator of efficacy and may accelerate regulatory timelines.
- Planned supplemental BLA filing in H2 2026 signals a clear regulatory and commercialization path for an expanded indication.
- Strong safety and infection profile set ATEV apart from current standard of care, potentially supporting rapid clinical adoption if approved.
- Presentation of results at a major clinical meeting (SVS VAM) to drive visibility among key opinion leaders and potential commercial partners.
Forward-Looking Statements and Risks
This update includes forward-looking statements subject to risks and uncertainties, including regulatory, clinical, and market acceptance factors. Investors should review the company’s SEC filings for additional risk disclosures.
Contact Information
Investor Contact:
Joyce Allaire, LifeSci Advisors LLC
+1-617-435-6602
[email protected]
[email protected]
Media Contact:
Rich Luchette, Precision Strategies
+1-202-845-3924
[email protected]
[email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making any investment decisions. The information is based on a company press release and may be subject to change or updates. Humacyte’s product candidates are investigational for uses other than the currently approved indications and are not approved for sale by the FDA or other regulatory agencies for all indications discussed.
